The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of triweekly cisplatin regimens in definitive chemoradiotherapy for locally advanced head and neck cancer: A propensity score matching analysis.
 
Yu Fujiwara
No Relationships to Disclose
 
Yasuyoshi Sato
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Naoki Fukuda
Honoraria - Eisai
Speakers' Bureau - Eisai
 
Naomi Hayashi
No Relationships to Disclose
 
Xiaofei Wang
No Relationships to Disclose
 
Kenji Nakano
No Relationships to Disclose
 
Akihiro Ohmoto
No Relationships to Disclose
 
Tetsuya Urasaki
No Relationships to Disclose
 
Mayu Yunokawa
No Relationships to Disclose
 
Makiko Ono
No Relationships to Disclose
 
Junichi Tomomatsu
No Relationships to Disclose
 
Takashi Toshiyasu
No Relationships to Disclose
 
Hiroki Mitani
No Relationships to Disclose
 
Shunji Takahashi
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); PharmaMar (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis